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Abstract 
The present diploma thesis is part of the project “Molecular Epidemiology of Colorectal 
Cancer”, and intends to develop a polygenic model of biomarkers in order to identify 
high-risk individuals and offer new insights into the prevention and treatment of 
colorectal cancer (CRC). With more than 4500 new incidence cases a year CRC 
represents one of the most common cancers in Austria. The telomerase reverse 
transcriptase (TERT) gene is essential for telomere length maintenance and stability in 
cancer cells. Genetic polymorphisms in the TERT gene may contribute to interindividual 
differences in the chromosomal stability and as a result influence individual colorectal 
polyp and CRC susceptibility. CRC is a multifactorial disease, environmental factors and 
genetic predisposition contribute to its development. Genetic factors include rare, but 
highly penetrant mutations and the more common genetic polymorphisms. In a case-
control study, consisting of 182 colorectal carcinoma patients, 332 high-risk polyp 
patients, 1065 low-risk polyp patients and 1822 colonoscopy negative controls, five 
selected single nucleotide polymorphisms (SNPs) within the TERT were genotyped using 
the 5’ nuclease TaqMan MGB Assay. No significant overall association was found for 
the genotyped SNPs and colorectal cancer risk. However, a significant increased risk for 
high-risk polyps was seen among homozygous carriers of the intronic SNP rs2075786. 
As a consequence, these results suggest potential involvement of genetic variation in 
susceptibility to colonic polyps. However, investigations in larger cohorts are required to 
establish rs2075786 as a possible biomarker for high-risk colonic polyps, and to further 
characterize the effect of multiple genetic polymorphisms within telomere stability genes 
on colonic polyps and CRC risk. 
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Zusammenfassung 
Die vorliegende Diplomarbeit ist Teil des laufenden Projekts „Molekulare Epidemiologie 
des kolorektalen Karzinoms” mit dem Ziel, ein polygenetisches Modell zu entwickeln um 
Patienten mit hohen Risikoprofilen zu identifizieren und neue Ansätze in der Prävention 
und Therapie des kolorektalen Karzinoms (KRKs) zu entwickeln. Mit über 4500 
Neuerkrankungen jährlich zählt das KRK zu den häufigsten Krebserkrankungen in 
Österreich. Das Telomerase Reverse Transkriptase (TERT) Gen ist verantwortlich für die 
Erhaltung und Stabilität der Telomere in Krebszellen. Genetische Polymorphismen im 
TERT Gen könnten die chromosomale Stabilität und folglich das Risiko für 
Kolonpolypen und dem KRK beeinflussen. Das KRK ist eine multifaktorielle 
Erkrankung. Neben umweltbedingte Risikofaktoren können auch genetische 
Prädispositionen zur Entstehung des Tumors führen. Zu den genetischen Faktoren 
zählen seltene, hochpenetrante Mutationen sowie häufig vorkommende genetische 
Polymorphismen. In einer Fall-Kontroll Studie, bestehend aus 182 KRK Patienten, 332 
Patienten mit Hochrisiko-Polypen, 1065 Patienten mit Niedrigrisiko-Polypen und 1822 
Teilnehmern mit einem negativen Koloskopiebefund wurden die Genotypen von fünf 
ausgewählten “Single Nucleotide Polymorphisms” (SNPs) im TERT Gen, mittels dem 5’ 
Nuklease TaqMan MGB Assay bestimmt. Es konnte kein Zusammenhang zwischen den 
genotypisierten SNPs und einem veränderten KRK Risiko nachgewiesen werden. 
Homozygote Träger des intronischen SNPs rs2075786 wurden jedoch mit einem 
signifikant erhöhten Risiko für Hochrisiko-Polypen assoziiert. Die Ergebnisse dieser 
Studie weisen auf einen möglichen Einfluss genetischer Varianten auf die Suszeptibilität 
für Kolonpolypen hin. Weitere Studien in größerem Ausmaß sind jedoch erforderlich um 
rs2075876 als Biomarker zu validieren und den Einfluss von multiplen Polymorphismen 
in Telomerstabilitäts-Genen auf das kolorektale Polypen und KRK Risiko zu 
untersuchen. 
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1. Introduction 
1.1 Epidemiology  
Colorectal cancer (CRC) is one of the major malignancies in the Western World. 
Worldwide the incidence of CRC varies widely, with a 25-fold variation between different 
countries. High incidences are reported from developing countries like North America, 
Australia, New Zealand and Japan. In contrast, incidence rates are low in Africa and 
Asia, and moderate in Southern parts of South America. Incidence rates also vary 
considerably within Europe. Geographic patterns show high incidences in Western and 
Eastern Europe, with the highest risk areas in the Czech Republic and Hungary (Parkin 
DM, 2004). These geographic variations probably reflect the influence of external and 
sociocultural factors on developing CRC. Indeed, changes in incident patterns from 
several migrant studies support the major role of environmental exposure and lifestyle 
factors on the etiology of this disease. Migrants quickly adopt patterns of new 
communities and lose the risk associated with their original home community within 
one generation (Boyle and Langman, 2000; Flood et al, 2000).  
With an estimated rate of 195.400 new incidence cases in 2006, CRC was the third most 
common cancer in European men and the second most common form of cancer in 
European women. Accounting for about 12.2% of total cancer deaths in 2006, CRC 
represents one of the leading causes of cancer death in Europe, distributed almost 
equally among men and women (Ferlay et al, 2007). However, favorable patterns for 
both genders are observed in most of the European countries, with the exception of some 
Mediterranean (Greece, Portugal, Spain) and Eastern European (Bulgaria, Poland, 
Romania) countries (Fernández et al, 2005). Furthermore, CRC survival in Eastern 
European countries is lower than the European average. These substantial differences 
are probably related to differences in the stage at diagnosis and to the quality of 
therapeutic approaches (Gatta et al, 2000; Coleman et al, 2003).  
 
In Austria a total of 4857 CRC cases were diagnosed in 2006, wherein cumulative rates 
showed striking variations by geographic area, with a clear east-west divide and the 
highest incidence rates in the Province of Burgenland (Statistik Austria, 2009a). With 
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about 2349 cancer deaths, it was the second major cause of cancer death in 2006 in both 
genders, exceeded only by lung cancer (Statistik Austria, 2009b). Nevertheless, the first 
study on survival data concerning Austria showed an increased 5-year survival rate in 
colon and rectal cancer patients compared to earlier results, probably explained by the 
effect of earlier detection and better therapeutic treatment (Haidinger et al, 2006). 
 
1.2 Histopathology of colorectal cancer 
The vast majority (95%) of CRCs are adenocarcinomas arising from the columnar 
surface epithelium and showing in some cases a mucinous component. Further rare 
malignancies of the large bowel include signet-ring cell carcinomas, squamous 
carcinomas, melanomas and lymphomas. In contrast, carcinoid tumors are seen rather 
frequently and are most common in the appendix. The anatomic distribution of cancers 
throughout the colon varies, but the majority of neoplastic lesions are located distal to 
the splenic flexure (60-70%), particularly in the sigmoid and descending colon. 
However, the literature demonstrates a steady migration of CRCs from distal to more 
proximal sites. It is still unclear whether this represents a true biological effect or only a 
consequence of a wider use of colonoscopy (Ponz de Leon and Di Gregorio, 2001). In 
addition, several factors such as increased age, female gender and the presence of 
comorbid illness are associated with a greater likelihood of developing CRC in a 
proximal location. Finally, proximal cancers have a tendency to present at a more 
advanced stage and therefore have a poorer prognosis (Gonzalez et al, 2001). 
Generally, the prognosis of CRC is directly related to the stage of the tumor at time of 
diagnosis. Although there are several different staging systems, one of the most widely 
used is the Dukes’ classification system established in 1932. To assess the best possible 
prognosis and to determine the treatment of patients, the system involves four different 
stages (Table 1). The Dukes’ Stage A refers to invasive cancer confined to the submucosa 
without the involvement of lymph nodes. Stage B lesions are subdivided, including 
tumors invading the muscularis mucosae and tumors extending into the surrounding 
serosa. Dukes’ Stage C is defined by the presence of lymph nodes, subdivided into C1 and 
C2. Stage D is characterized by the presence of distant metastases. There are substantial 
differences in survival according the stage of disease. Patients with Dukes’ A have an 
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excellent prognosis, their 5-year survival rate is close to 100%. 5-year survival´rates in 
Dukes’ B is about 80-85%, dropping to 50-70% in Dukes’ C. The age-adjusted 5-year 
survival rate for colorectal adenomas is merely about 14% for Dukes’ D (Yamada T, 
1998). 
 
Table 1. Dukes’ classification of colorectal tumors (based on Yamada T, 1998) 
 
Stage 
 
Depth of invasion 
 
Frequency 
(%) 
 
 
Age-adjusted 5 year-survival 
(%) 
 
A 
 
Submucosa 
 
 
15 
 
95-100 
 
B1 
B2 
 
Muscularis propria 
Serosa 
 
 
>31 
 
80-85 
 
C1 
C2 
 
1-4 lymph nodes 
> 4 lymph nodes 
 
 
>23 
 
50-70 
 
D 
 
 
Distant metastases 
 
30 
 
5-15 
 
However, there has been a gradual move from using Dukes classification to using the 
tumor-node-metastasis (TNM) classification, describing and recording more accurately 
the anatomic extent of the cancer. The staging is based on four classifying individual 
elements: the primary site (T), usually divided into T1 to T4, the presence or absence of 
regional lymph nodes (N), and the presence or absence of metastasis beyond the 
regional lymph nodes (M) (Greene and Sobin, 2008). 
The overall prognosis and treatment choice for CRC is also related to the degree of 
differentiation i.e. the degree of similarity of tumor architecture to the structure of the 
organ from which the tumor arose. Tumors are stratified into four different histological 
grades (well differentiated, moderately differentiated, poorly differentiated and 
anaplastic). While a well-differentiated tumor will have a relatively good prognosis, the 
anaplastic grade is typical of a rapidly growing malignant tumor (Taylor et al, 1999). 
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1.3 Histopathology of colorectal polyps 
Some CRC may develop “de novo”, but substantial evidence supports the importance of 
colonic polyps as a precursor in the development of CRC (Ponz de Leon and Di Gregorio, 
2001). Morphologically a polyp is defined as any elevation or protrusion of mucosal 
surface and in general colonic polyps are classified into neoplastic and non-neoplastic 
polyps (Table 2), wherein adenomatous and hyperplastic are the most commonly 
detected types (Markowitz and Winawer, 1997; Colucci et al, 2003).  
The vast majority of CRCs arise from premalignant transformation of an adenomatous 
polyp with a prevalence of 35% in Europe (Midgley and Kerr, 1999). Adenomas are 
monoclonal expansions of mutated epithelial stem cells (Bond JH, 2000), resulting from 
disordered cell replication and differentiation in the upper portions of the crypt (Ponz de 
Leon and Di Gregorio, 2001). However, of the remaining adenomas, only a small 
proportion is estimated to become malignant. An adenoma can be considered malignant 
when neoplastic cells have invaded down through the muscularis mucosa into the 
submucosa (Markowitz and Winawer, 1997). Colorectal adenomas are observed in all 
tracts of the large bowel and are quite rare under the age of 30 years, becoming more 
common with increased age (Cannon-Albright et al, 1994). Due their different 
manifestations of abnormal tissue architecture, colonic adenomas are divided 
histologically into tubular, tubulovillous and villous adenomas (Table 2) (Markowitz and 
Winawer, 1997; Colucci et al, 2003). 
 
Table 2. Classification of colorectal polyps (based on Colucci et al, 2003) 
 
Histological classification 
 
 
Polyp Type 
 
Malignant potential 
 
Non-neoplastic 
 
 
 
Hyperplastic polyps 
Hamartomas 
Lymphoid aggregates 
Inflammatory polyps 
 
 
No 
 
 
Neoplastic (adenomas) 
 
Tubular adenomas  
(0-25% villous tissue) 
Tubulovillous adenomas  
(25-75% villous tissue) 
Villous adenomas  
(75-100% villous tissue) 
 
 
Yes 
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Data from the National Polyp Study and St. Mark’s Hospital have demonstrated that 
approximately 75-87% of adenomas are primarily tubular in architecture, 8-15% 
tubulovillous, and the residual 5-10% are villous (Muto et al, 1975; O’Brien et al, 1990). 
All types of adenomas exhibit some degree of dysplasia, graded into mild, moderate and 
severe, and determined by the degree of cytological epithelial atypia and glandular 
architectural distortion (Markowitz and Winawer, 1997). The National Polyp Study has 
shown that about 86% of adenomas show mild, 8% moderate, and 6% severe dysplasia 
(O’Brien et al, 1990). A severe dysplasia in an adenoma is considered as a selective 
marker for an increased risk in cancer. Probably most of the CRCs evolve through stages 
of increasingly severe dysplasia before becoming invasive lesions (Ponz de Leon and Di 
Gregorio, 2001). Additionally, the risk of an adenoma harboring a high-grade lesion or 
invasive adenocarcinoma is associated with larger polyp size and increased patient age 
(O’Brien et al, 1990). Furthermore, the St. Marks Hospital Study demonstrated an 
association of villous histology with an increased risk of malignancy. 4.8% of tubular 
adenomas, 22.5% of tubulovillous and about 40.7% of villous adenomas were malignant 
(Muto et al, 1975).  
In 2006, Winawer et al, proposed new guidelines for colonoscopy surveillance after 
polypectomy, stratifying patients into those at lower or higher risk for a subsequent, 
advanced neoplasia. While patients with an increased risk have either three or more 
adenomas, or high-grade dysplasia, or villous features, or an adenoma (≤1cm), patients 
with low risk include those with one or two small tubular adenomas (≤1cm) with no 
high-grade dysplasia. 
 
1.4 Molecular genetics of colorectal tumorigenesis 
A fundamental paradigm for the pathogenesis of CRC is the adenoma-carcinoma 
sequence. According to this proposed genetic model, progressive accumulation of 
various, genetic alterations including the inactivation of tumor suppressor genes and the 
activation of proto-oncogenes, provides the stepwise pathological transformation of 
premalignant adenomas to invasive carcinoma. Although the alterations often occur 
according to a preferred sequence, the total accumulation rather than their order of 
occurrence seems to be most important in the development of CRC. The molecular 
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events themselves provide the epithelial cells with a growth advantage, leading to a 
clonal expansion of neoplastic cells (Fearon and Vogelstein, 1990). However, the 
neoplastic transformation of normal epithelial cells to early adenomas to invasive cancer 
is extremely variable, and a significant proportion of cases may arise through an 
alternative molecular pathway to the Vogelstein model (Smith et al, 2006). Important 
molecular events and processes driving colorectal carcinogenesis are therefore 
continually refined. However, the loss of genomic instability, in the form of 
chromosomal (CIN) or microsatellite instability (MSI) seems to be a crucial event for the 
pathological progression in CRC carcinogenesis. It provides a permissive cellular 
environment and accelerates the neoplastic process, ensuring subsequent strategic 
mutations. There is sound evidence that most CRC cases develop via the CIN pathway, 
resulting in an accumulation of numerical or structural abnormalities and a frequent loss 
of heterozygosity (LOH) (Worthley et al, 2007).  
It is believed that aberrant crypt foci (ACF) are the earliest histological lesions in this 
pathway, harboring important genetic alterations for the development of CRC. 
Dysplastic ACFs in particular show the highest malignant potential, harboring mutations 
in the tumor suppressor gene adenomatous polyposis coli (APC) (Smith et al, 1994; 
Takayama et al, 1998). As a result, heterogeneous mutations in the APC gene are one of 
the earliest genetic changes associated with CRC carcinogenesis, and probably represent 
important key events for its initiation (Powell et al, 1992). Beside somatic APC mutations 
in sporadic CRC cases, germline mutations in the APC locus are responsible for the rare, 
inherited familial adenomatous polyposis (FAP) syndrome. The APC gene has a 
gatekeeper function in the colonic cell proliferation, it encodes a large protein with 
several functional domains, playing a role in the Wnt signaling pathway and the 
intercellular adhesion (Kinzler and Vogelstein, 1996). Loss or mutation of the gene 
results in a truncated protein, inducing polyp formation as a result of the loss of orderly 
cell proliferation, apoptosis, cell migration and mitosis (Villa E, 2000). Whether 
mutations in the tumor suppressor gene APC are particularly crucial and probably 
sufficient for the initiation of CRC carcinogenesis, several other genetic events are 
involved in the further tumor progression (Powell et al, 1992; Kinzler and Vogelstein, 
1996). Candidate genes include the proto-oncogene K-ras (on chromosome 12p), the 
tumor suppressor gene p53 (on chromosome 17p) as well as allelic losses on 
chromosome 18q, containing the deleted in colorectal carcinoma (DCC) gene. While K-
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ras mutations are believed to occur early, allelic deletions on 17p and 18q seem to be late 
events in the neoplastic process (Fearon and Vogelstein, 1990). 
Approximately 85% of all CRC cases develop via the chromosome stability pathway 
(Grady WM, 2004), while the remaining sporadic and most hereditary nonpolyposis 
colorectal cancer (HNPCC) cases follow a different pathway, the phenotype of MIN. MIN 
results from a failure in the mismatch repair system and is characterized by a dramatic 
increase in genetic errors, fuelling the process of oncogenesis (Hoeijmakers JH, 2001). 
 
1.5 Molecular epidemiology 
In 1982, Perera and Weinstein introduced the term “molecular cancer epidemiology” as 
a new multidisciplinary approach in cancer research and prevention, in which advanced 
laboratory methods are used in combination with analytical epidemiology, to determine 
at the biochemical or molecular level specific exogenous agents or host factors, playing a 
critical role in human cancer pathogenesis (Perera and Weinstein, 1982). The 
incorporation of a wide range of biomarkers into epidemiologic studies should thereby 
provide a useful tool, having enormous potential in identifying risk populations with 
greater susceptibility and improving the exposure assessment. The biomarkers were 
generally categorized as markers of (1) internal dose, (2) biologically effective dose, (3) 
preclinical biological effects and (4) markers of susceptibility (Perera and Weinstein, 
1982; Perera and Weinstein, 2000). Biomarkers of internal dose take into account 
individual differences in the absorption, the metabolism or the bioaccumulation of the 
substance and indicate the actual level of the compound or its metabolites within body 
tissues or excretions. Examples include cotinine, resulting from cigarette smoking 
exposure or 1-hydroxpyrene urinary levels from exposure to polycyclic aromatic 
hydrocarbons (PAHs). However, markers of internal dose do not indicate the amount of 
which a given compound has interacted with critical cellular targets. Therefore assays 
have been developed to measure the biologically effective dose of a compound, i.e. the 
amount of the activated agent that has actually reacted with the critical cellular 
macromolecules, such as DNA, RNA or proteins. The next category includes marker of 
early biological effects resulting from exposure and measured directly in the target tissue 
or in a surrogate source of cells. Representative biomarkers assess various types of 
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genotoxicity, including chromosomal aberrations, gene mutations, the activation of 
oncogenes and the inactivation of certain tumor suppressor genes (Perera and 
Weinstein, 2000). For example, the p53 tumor suppressor gene is mutated in about 40-
50% of lung, breast, colon and other common cancers (Perera FP, 1997). The fourth and 
last category of biomarkers includes those related to inherited or acquired variations in 
host susceptibility, modulating the individual response to environmental carcinogens. 
This category is a promising area of research, providing insights into interindividual 
variation in human cancer risk and the complex interactions between environment and 
susceptibility factors in the multi-step process of carcinogenesis (Perera and Weinstein, 
2000). Genetic influence on carcinogenesis is quite variable and ranges from highly 
penetrant mutations, accounting for a small proportion of incidences, to other more 
common low-penetrance mutations that influence individual biological response to 
environmental carcinogens (Perera FP, 1997). The detection and identification of low-
penetrance mutations in genetic predisposition is of great importance especially in those 
cancers associated with lifestyle factors, such as diet, tobacco and alcohol (Kotnis et al, 
2005). 
 
1.5.1 Single nucleotide polymorphism 
The most abundant and simplest genetic variation in the human genome takes the form 
of a stable inherited substitution of a single base, termed single nucleotide 
polymorphism (SNP). By the traditional definition a SNP has a minor allele frequency 
(MAF) of 1% or more in at least one population (Kruglyak and Nickerson, 2001). SNPs 
are dispersed throughout the genome and can be found at least on every 0.3-1 kilobase, 
suggesting an estimated total number of more than 15 million available SNPs in the 
human genome (Schork et al, 2000; Salisbury et al, 2003). While most of them are silent 
and do not alter the function or expression of a gene, an estimated 50.000-250.000 of 
SNPs will actually confer small to moderate biological effects (Chanock S, 2001; 
Erichsen and Chanock, 2004). For example, SNPs in coding regions may directly impact 
the protein function, while a SNP in a promoter region can influence gene expression 
(Schork et al, 2000). Functional polymorphisms are expected to have lower allele 
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frequencies and in fact the vast majority of coding region SNPs causing an amino acid 
change have an allele frequency below 5 % (Kruglyak and Nickerson, 2001).  
Individuals carrying a particular allele at one locus often predictably carry specific alleles 
at other nearby variant sites, known as linkage disequilibrium (LD) (International 
HapMap Consortium, 2005). Blocks of SNPs in the same chromosomal region are not 
inherited randomly, but as a set of polymorphism alleles (haplotye blocks). Systematic 
studies of common polymorphisms are facilitated by the analysis of markers inherited 
on a haplotype (Erichson and Chanock, 2004). This block-like structure of LD and the 
existence of areas of low or high recombination rate lead to the identification of tagging 
SNPs (tSNPs), SNPs that are correlated with and can therefore be used to predict with a 
relatively high probability the set of alleles at other co-segregating tSNPs (Beckmann et 
al, 2007). 
The ongoing discovery of SNPs and the characterization of haplotypes in human 
populations are having a fundamental impact on cancer biology, being a remarkable tool 
to investigate the interindividual differences in treatment response and the outcome of 
specific cancers (Erichsen and Chanock, 2004; Rebbeck et al, 2004). In addition, SNP 
and haplotype analysis may provide new insights into the complex correlation of 
exposure and cancer, having future implications for primary preventive (lifestyle, 
chemoprevention) and early intervention strategies (Erichsen and Chanock, 2004). 
 
1.5.2 Molecular epidemiology of colorectal cancer 
Several lifestyle factors have been associated with an increased CRC risk. Indirect 
evidence based on international differences in incidence patterns as well as migrant 
studies supports the importance of environmental risk factors on the etiology of CRC 
(Boyle and Langman, 2000; Parkin DM, 2004). 
Dietary components have been estimated to determine up to 90% of the international 
difference in CRC incidence (Willett WC, 1989). Their protective or predisposing effect 
on CRC was investigated in several epidemiologic studies. There is sound evidence that a 
high intake of dietary fat and meat increases CRC risk (Willett et al, 1990), although 
controversial results exist (Flood et al, 2003). Heterocyclic amines, formed during 
certain cooking practices may be important carcinogens, and the individual risk may be 
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modified by polymorphisms in their metabolizing enzymes (Lang et al, 1994; Cheng et 
al, 1998). On the contrary, the consumption of dietary fibre has often been proposed to 
have a protective effect on CRC risk, however epidemiologic studies reported differences 
in the effect of components. Based on their physiologic function, components are 
commonly classified into insoluble, non-degradable constituents (mainly in cereal fibre) 
and soluble, degradable constituents (mainly present in fruit and vegetables) (Boyle and 
Langman, 2000). Most of the studies found no protective effect of cereal fibre, but found 
an inverse association with the total fruit and vegetable consumption and CRC risk 
(Steinmetz et al, 1991; Terry et al, 2001).  
Furthermore, evidence indicates that tobacco smoking is one important risk factor of 
non-dietary origin. Long-term heavy cigarette smokers show a 2-3 fold elevated risk of 
developing CRC (Giovannucci E, 2001). In contrast, inverse associations have been 
demonstrated with increased physical activity (Colditz et al, 1997) and endocrine factors, 
like menopausal hormones (Hébert-Croteau N, 1998). Additionally, evidence is strong 
that non-steroidal anti-inflammatory drugs (NSAIDs), like aspirin seem to have a 
protective effect on CRC risk (Rosenberg et al, 1998). This beneficial effect has been 
ascribed to the inhibition of the cyclooxygenase 2 (COX-2), an enzyme central to the 
prostaglandin synthesis (Ulrich et al, 2006).  
Several other environmental risk factors for CRC have been postulated, while some of 
the associations are still controversial, in having either a protective or causative effect 
(Boyle and Leon, 2002). 
CRC is a multifactorial disease, beside the environmental risk factors, genetic 
predispositions contribute to an increased risk of developing CRC (De Jong et al, 2002). 
Since 1982 the molecular epidemiology has contributed to growing awareness of the 
importance of common genetic and acquired susceptibility factors in modulating risks 
from environmental carcinogens (Perera and Weinstein, 2000). Furthermore, CRC is 
one of the cancers for which most is known about the genes affected by cancer-causing 
mutations, their normal functions and their effects on carcinogenesis when they are 
mutated (De la Chapelle A, 2004). 
 
• High-penetrance mutations  
The role of high-penetrance mutations in CRC pathogenesis is well understood. 
Although, only a small proportion of all CRC incidence can be ascribed to highly 
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penetrant causative mutations, showing a strong hereditary component, a high lifetime 
risk and little environmental influence. Rare genetic syndromes conferring a high 
lifetime risk for CRC include FAP and HNPCC also known as Lynch Syndrome (De la 
Chapelle A, 2004).  
The autosomal dominant syndrome FAP has a penetrance of ∼100% and is caused by 
germline mutations in the gatekeeper gene APC, wherein the vast majority are nonsense 
or truncating mutations. Clinically the syndrome is characterized by an abnormal 
number of adenomatous polyps in the colon and rectum and extra colonic features, 
appearing during the second and third decades of life (Kinzler and Vogelstein, 1996; De 
la Chapelle A, 2004).  
The genetic basis for the second inherited form, the HNPCC is caused by germline 
mutations of mismatch repair genes. Mutations in the hMSH2 and hMLH1 are 
responsible for a large majority of HNPCC cases (Peltomäki and de la Chapelle, 1997), 
several other mutations (hMSH6, hPMS1 and hPMS2) account for most of the remaining 
cases (Potter JD, 1999). Most clearly clinical features of HNPCC include a tendency to 
early onset and the predisposition to cancers of at least seven other organs 
(endometrium, stomach, ovaries, small bowel, hepatobiliary epithelium, uroepithelial 
epithelium and brain). Together the hereditary syndromes account for less than 5% of all 
colon cancer cases (De la Chapelle A, 2004). 
 
• Low-penetrance mutations  
The inherited cause of about 20-30% of all CRC cases (Grady WM, 2003) and a two fold 
risk in first degree relatives suggests that low-penetrance genes are responsible for the 
remaining familiarity of CRC cases and also for a high proportion of sporadic cases (De 
Jong et al, 2002). In contrast to high-penetrance mutations, the understanding of their 
influence on colorectal carcinogenesis is far less advanced. It is believed that common 
genetic traits pose a low individual risk, but could be important determinants of the high 
population attributable risk. Thus, the effect of low-penetrance mutations on the 
variation of CRC susceptibility is essential for understanding disease etiology and also 
for the development of new diagnostic, therapeutic and preventive strategies (De la 
Chapelle A, 2004).  
The identification of biologically meaningful and disease causing genetic variants is the 
key challenge for genetic association studies (Rebbeck et al, 2004). Low-penetrance 
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alleles of extremely variable genes are implicated in the susceptibility for CRC and their 
selection requires detailed knowledge of biochemical and physiological pathways that 
are involved in the process of carcinogenesis (Kotnis et al, 2005). The candidate gene 
approach examines those genes that fit a plausible understanding of biology (Erichsen 
and Chanock, 2004). A number of promising susceptibility polymorphisms for CRC have 
emerged through this strategy. For example, there is strong evidence for significant 
associations between polymorphic variants in proinflammatory cytokines (like 
Interleukin 8) and an increased CRC and adenoma risk, highlighting the importance of 
the inflammatory processes implicated in the susceptibility of this disease (Gunter et al, 
2006; Küry et al, 2008). Despite inconsistent results, there is also some evidence that 
the methylenetetrahydrofolate reductase (MTHFR), implicated in the folate metabolism, 
may represent one of the key players in CRC susceptibility. A meta-analysis supported 
the different role of MTHFR polymorphisms (C677T and A1298C) in colorectal adenoma 
and CRC. The 677T allele showed a small but significant protective effect against CRC 
compared with the 677C allele for a worldwide population. In contrast, a significantly 
decreased CRC risk was reported for the 1298C allele (Huang et al, 2007). In addition, 
genes involved in DNA repair have an important role for protecting the genome from 
cytotoxic damage caused by endogenous and exogenous agents and are of crucial 
importance as suppressors of carcinogenesis (Ishikawa et al, 2001). Hence, their altered 
function probably affects CRC risk. However, partly inconclusive data suggests that the 
individual cancer risk depends not only on a single SNP, but on a joint effect of multiple 
polymorphisms within different genes or pathways (Naccarati et al, 2007). 
Candidate genes represent only a subset of the actual genes with variants that affect 
cancer risk (Rothman et al, 2001). The promising approach of genome-wide association 
(GWA) studies makes it possible to identify further common variants implicated in CRC 
susceptibility, without having to rely on choosing a priori candidates (Rebbeck et al, 
2004). A current meta-analysis of GWA studies identified genetic variation in the bone 
morphogenetic protein 4 preproprotein (BMP4), a member of the transforming growth 
factor beta (TGF-β) family, as a susceptibility allele for CRC. In addition, three other 
previously unreported polymorphisms influencing CRC susceptibility were identified. 
These include: cadherin 1 (CDH1), having an established role in CRC carcinogenesis, the 
Rho GTPase binding protein 2 (RHPN2), involved in the regulation of the actin 
cytoskeleton and cell motility, and the region 20p12.3, rich in genes or predicted protein-
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encoding transcripts (Houlston et al, 2008). Moreover, a susceptibility locus on 11q23, 
tagged by rs3802842, seems to be associated with CRC risk (Tenesa et al, 2008). The 
functional role of genetic variation in the 8q24 locus, as a risk factor for CRC was 
demonstrated in several GWA studies (Haiman et al, 2007; Tomlinson et al, 2007; 
Zanke et al, 2007). Furthermore, there is strong evidence suggesting that 
polymorphisms in mother against decapentaplegic homolog 7 (SMAD7) involved in the 
TGF-β and Wnt signaling are associated with CRC (Broderick et al, 2007). Both risk loci 
(8q24 and 18q21) were additionally confirmed by a recent meta-association study 
(Curtin et al, 2009).  
 
Although GWA studies make it possible to scan the entire genome for associations, the 
candidate gene approach remains viable and also critical to confirm possible 
susceptibility genes identified by genome-wide approaches. In fact, candidate gene 
approaches have the advantage of maximizing the inferences about biological plausibility 
and the causality of complex diseases, like cancer (Rebbeck et al, 2004). Representative 
and promising candidate genes for CRC association studies are involved in the 
inflammation pathway, in the carcinogen metabolism, the DNA repair and in cell 
senescence and mortality, like telomerase (Houlston and Tomlinson, 2001). 
 
1.6 Telomerase 
Telomeres at eukaryotic chromosome ends are specialized structures composed of 
simple, tandemly repeated sequences and specific proteins (Blackburn EH, 1991). 
Functional telomeres protect chromosomal ends from degradation, aberrant 
recombination and end-to-end fusion and are therefore crucial for maintaining genomic 
stability and integrity. Due the inability of conventional DNA polymerase to fully 
replicate the single 3’ end overhang of the lagging strand (the end replication problem), 
loss of telomeric DNA occurs with each cell division. Thus, telomeres progressively 
shorten with each replication to a critical length, resulting in genomic instability and 
cellular senescence. In contrast to most somatic cells; germ cells, embryonic stem cells 
and cancer cells circumvent telomere-mediated senescence by activation or inactivation 
of alternative pathways (Cong et al, 2002). The vast majority of human cancers express 
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high levels of telomerase activity (Shay and Bacchetti, 1997), a ribonucleoprotein enzyme 
responsible for the replication of chromosomal ends, providing the molecular basis for 
unlimited cell proliferation, through the addition of simple TTAGGG repeats (Blackburn 
EH, 2000). In human cells this holoenzyme constitutes a template RNA component 
(TERC) (Feng et al, 1995) and a reverse transcriptase (TERT), representing the catalytic 
protein subunit (Weinrich et al, 1997). The TERT gene is located on chromosome 5, 
compromising 16 exons and 15 introns (Cong et al, 1999). 
In contrast to the ubiquitous expression of the RNA subunit, TERT is only expressed in 
embryonic stem cells and germ cells. In about 90% of human cancers, activated 
telomerase is responsible for telomere maintenance (Mathieu et al, 2004), although 
alternative mechanisms of telomere lengthening exist (Bryan et al, 1997). The important 
role of telomere stabilization was first described by Hahn et al, 1999a. They 
demonstrated that ectopic expression of the catalytic subunit TERT, and two oncogenes 
(largeT, ras) is sufficient for the tumorigenic conversion of human epithelium and 
fibroblast cells. Moreover, inhibition of the telomerase enzyme activity limited the 
growth of human cancer cells in vitro and also their tumorigenic pathway in vivo (Hahn 
et al, 1999b). 
Several studies demonstrated an association between a high telomerase activity and CRC 
(Chadeneau et al, 1995; Engelhardt et al, 1997) and proposed an increased level of 
telomerase activity as an independent prognostic indicator of poor outcome in patients 
with CRC (Tatsumoto et al, 2000). In addition to the influence of telomerase activity on 
colorectal carcinogenesis, prognostic potential of TERT expression (Gertler et al, 2002; 
Gertler et al, 2004) and telomere length was reported (Gertler et al, 2004).  
Telomere stability genes, including TERT, show a limited degree of nucleotide diversity 
and have a vital function in chromosomal integrity. Thus, genetic variation in these 
genes may not be well tolerated (Savage et al, 2005). The functional, polymorphic 
sequence -1327 T/C in the promoter region of TERT was associated with higher 
transcriptional activity, longer telomere length and an increased telomerase activity 
(Matsubara et al, 2006). Previous studies identified polymorphisms in several 
components of the telomerase complex as risk factors associated with rare and complex 
disorders, like cancer. Functionally important mutations in the TERT gene may be risk 
factors for marrow failure, impairing the telomerase activity by haploinsufficiency 
(Yamaguchi et al, 2005). A recent study from Savage et al, (2007) demonstrated an 
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association between genetic polymorphisms (-1381C>T, -244C>T, Ex2-659G>A) in 
TERT with reduced breast cancer risk, in individuals with a family history of breast 
cancer (Savage et al, 2007). 
 
1.7 Aim of the study 
The aim of the present thesis was to investigate whether any of the five genotyped SNPs 
within the TERT gene are associated with colorectal polyps or CRC risk.  
The study population was recruited within a large CRC screening project in the Province 
of Burgenland and three hospitals in Vienna, consisting of 182 colorectal carcinomas, 
1397 colorectal polyps and 1822 controls. The genotypes of the colonoscopy negative 
control group have been compared with three different risk groups, namely colorectal 
carcinoma group, high-risk and low-risk polyp group. 
The recent study is part of the project “Molecular Epidemiology of Colorectal Cancer” 
with the main purpose of developing a polygenetic model for CRC and the aim to identify 
high-risk individuals and to allow more effective prevention and treatment strategies. 
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2. Material and Methods 
2.1 Study population 
The study population was recruited within the area wide Austrian project “Burgenland 
gegen Dickdarmkrebs“ initiated by Dr. Karl March (KH Oberpullendorf). This large 
screening project targeted female and male inhabitants of the Province of Burgenland, 
aged 40-80 years. Subjects received an annual fecal occult blood test (FOBT)-screening 
with the purpose of decreasing carcinom-specific morbidity and mortality and improving 
the early diagnosis of CRC. More than 135.000 participants were included in this 
screening per year, wherein 2.500-3.000 patients with positive FOBTs received 
extensive diagnostic- work up. Between 2003 and 2007 a total of 3471 study participants 
were recruited within this molecular epidemiology project. Eligible cases included 
participants with a histologically confirmed, previously untreated CRC, newly diagnosed 
in this screening project. Further CRC cases were recruited from three hospitals in 
Vienna (Division of Oncology, Medical University of Vienna; Department of Surgery, 
SMZ Süd and Department of Gastroenterology, KH Rudolfstiftung). 
Demographic, anthropometric and lifestyle factors (tobacco use, dietary habits) were 
assessed by a short questionnaire. All participants provided written informed consent.  
For statistical analysis a classification in high-risk and low-risk groups was performed, 
depending on the villous tissue within the polyp (Table 3). The polyp group consisted of 
332 patients with high-risk polyps and 1065 patients with low-risk polyps. The control 
group included a total of 1822 individuals with a positive fecal occult blood test, who 
underwent colonoscopy without apparent pathological findings. 
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Table 3. Classification of polyps in high-risk and low-risk 
 
Classification 
 
Polyp Type 
 
 
High-risk group 
 
Adenomatous tubulovillous polyps 
Adenomatous villous polyps 
Adenomatous tubular and tubulovillous polyps 
 
 
Low-risk group 
 
Hyperplastic polyps 
Adenomatous tubular polyps 
 
 
2.2 Genomic DNA isolation 
The purification of human genomic DNA from peripheral blood was performed 
according the QIAamp DNA Blood Midi Kit spin protocol. (QIAGEN, Hilden 
Germany). 2 ml of each blood sample was added to 200 µl of QIAGEN Protease 
respectively, mixed briefly and incubated with 2.4 ml of lysis Buffer AL in a water bath 
(70°C) for about 30 minutes. After addition of 2 ml ethanol (100%) and mixing to obtain 
a homogenous solution, half of the solution was transferred into the midi column and 
centrifuged at 1850xg for 5 minutes. The DNA bound to the membrane was washed in 
two centrifugation steps (4000 rpm for 2 minutes, 4000 rpm for 18 minutes). The use of 
two different wash Buffers AW1 and AW2 improved the purity of DNA. Purified DNA 
was eluted with Buffer AE, incubated for 5 minutes and centrifuged at 4000 rpm for 
about 7 minutes.  
The DNA concentration was quantified spectrophotometrically at a wavelength of 260 
nm using the NanoDrop ND-1000 Spectrophotometer (PEQLAB Biotechnologie GMBH, 
Erlangen Germany). Samples were diluted with buffer AE to a working dilution of 10 
ng/µl and stored at -80°C. 
 
2.3 SNP selection 
Four tSNPs in TERT (rs2736098, rs4975605, rs2736100, rs2075786) with a MAF 
greater than 3.5% were picked out for the HapMap CEU population (www.hapmap.org). 
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An additional SNP in the promoter region of TERT (rs2736940) was selected from the 
publicly available SNP500Cancer database (www.snp500cancer.nci.nih.gov/home.cfm) 
because of its likely functional and phenotypic significance. As regards to the 
nomenclature we referred to the SNP500Cancer database. 
 
2.4 Genotyping of TERT polymorphisms 
Genotyping was performed on a 7500 Fast Real Time PCR System (Applied Biosystems, 
California US) using standard protocols and reagents.  
The TaqMan® pre-designed SNP Genotyping assay (Applied Biosystems, California US) 
was conducted using 96-well reaction plates optimized for 10 µl reactions. The 
genotyping reaction mix for a 10 µl approach with 2o ng DNA consisted of 2.875 µl Aqua 
bidestillata sterilis (Fresenius Kabi, Austria), 5 µl TaqMan® Genotyping Master Mix 
(Applied Biosystems, California US) and 0.125 µl 40X TaqMan® SNP Genotyping Assay. 
The TaqMan® Genotyping Master Mix contained all components except primers and 
probes. 
Standard cycling conditions were an initial denaturation step at 95°C for 10 minutes for 
the activation of the AmpliTaq Gold® Polymerase, followed by 40 cycles of 92°C for 15 
seconds (denaturation) and 60°C for 1 minute (anneal/extend). 
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2.4.1 TaqMan®  MGB probes and primers  
The TaqMan® SNP Genotyping assay included predesigned sequence specific primers 
and TaqMan® minor groove binder (MGB) probes (Table 4). Final concentrations of both 
primers (forward and reverse) were 36 µM, and for the probes 8 µM, respectively. 
 
Table 4. Predesigned TaqMan® MGB probes for genotyping TERT polymorphisms 
  
Component 
 
 
5’ dye 
 
Context sequence 
 
3’ dye 
 
Allele 
 
Probe 1 
 
VIC® 
 
GGATTAC[A/G]GGTCGCT 
 
NFQ/MGB 
 
T 
 
rs2735940 
-1381C>T 
Probe 2 FAM™ GGATTAC[A/G]GGTCGCT NFQ/MGB C 
Probe 1 VIC® GGGGGCC[C/T]GCGTGGT NFQ/MGB G rs2736098 
Ex2-659G>A 
Probe 2 FAM™ GGGGGCC[C/T]GCGTGGT NFQ/MGB A 
Probe 1 VIC® AAGAAAG[A/C]AAGCCTC NFQ/MGB T rs4975605 
IVS6-3133G>T 
Probe 2 FAM™ AAGAAAG[A/C]AAGCCTC NFQ/MGB G 
Probe 1 VIC® AAAGCTA[A/C]AGAAACA NFQ/MGB T rs2736100 
IVS2-3777G>T 
Probe 2 FAM™ AAAGCTA[A/C]AGAAACA NFQ/MGB G 
Probe 1 VIC® AGGAGCC[A/G]GGTCACC NFQ/MGB T rs2075786 
IVS10+269T>C 
Probe 2 FAM™ AGGAGCC[A/G]GGTCACC NFQ/MGB C 
 
 
2.4.2 Allelic detection with TaqMan® MGB probes  
The TaqMan® Genotyping Assay uses dual-labeled fluorogenic MGB probes to determine 
specific PCR products during the amplification reaction. The homogenous assay is based 
on two principles: 
the technology of fluorescence resonance energy transfer (FRET) and  
the 5’ nuclease activity of the AmpliTaq Gold® DNA Polymerase. 
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The TaqMan® MGB probes incorporate a non-fluorescent quencher (NFQ) dye at the 3’ 
end and a fluorescent reporter dye (VIC® or FAM™) at the 5’ base, along with a MGB 
moiety. The presence of two probes labeled with two different reporter dyes enables bi-
allelic genotyping. In the intact probe the reporter dye emission is adequately absorbed 
by the quencher due to the process of FRET. Primary conditions include close proximity 
of the fluorophors and overlapping of the absorption spectrum of the quencher with the 
emission spectrum of the reporter. After hybridization of the probe to the template 
strand, the 5’–3’ nuclease activity of the AmpliTaq Gold® DNA Polymerase cleaves the 
reporter dye from the probe. The distance dependent energy transfer is interrupted and 
the released reporter dye emits its characteristic fluorescence signal. Thus, the increase 
in fluorescence intensity indicates that the probe specific PCR product has been 
generated. Based on a substantial increase in the VIC® or FAM™ fluorescence signal, 
homozygous polymorphic genotypes can be detected. An increase in both signals 
correlates with a heterozygous genotype (Table 5) (Applied Biosystems, 2004). 
 
Table 5. Correlation between fluorescence signals and genotypes (based on Applied Biosystems, 2006) 
 
Substantial increase in: 
 
 
Indicates: 
 
VIC® fluorescence only 
 
Homozygosity for Allele 1 
 
FAM™ fluorescence only 
 
Homozygosity for Allele 2 
 
Both fluorescences 
 
 
Heterozygosity for both Alleles 
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Even single base mismatches between probe and targets reduce the efficiency of probe 
hybridization and destruction (Figure 1) (Livak KJ, 1999). 
 
 
Figure 1. Principle of mismatch discrimination with TaqMan® 5’ nuclease assay (Applied Biosystems, 
2006) 
 
Stable binding of perfectly matched probes compared to mismatches, improves allelic 
specific hybridization and the amount of reporter dye cleaved from a quencher. In 
addition, mismatched probes are more likely to be displaced from the target by the DNA 
Polymerase without degradation. Each of these factors contributes to a powerful 
mismatch discrimination and reduction of nonspecific fluorescence signals. Additional 
increase in mismatch discrimination is provided by the attachment of a MGB to the 3’ 
end of the TaqMan® probe. MGB´s are relatively long, crescent-shaped molecules, which 
bind isohelically to the minor groove of DNA through van der Waals contacts, 
hydrophobic and electrostatic interactions. Conjugated MGBs enhance the stability of 
hybrid duplexes, causing an increased melting temperature (Tm), which allows shorter 
probe sequences (Afonina et al, 1997; Kutyavin et al, 1997). Shorter fluorogenic probes 
exhibit greater differences in Tm values between perfectly matched and mismatched 
probes, thus resulting in increased sequence specificity (Applied Biosystems, 2004) 
 
Allelic discrimination is a multiplex assay, performed as an endpoint fluorescence 
reading using the 7500 Fast Real Time PCR System (Applied Biosystems, California US). 
The increase in fluorescence of the reporter dyes associated with the TaqMan® probes is 
measured by the sequence detection software (SDS). Corresponding normalized reporter 
(Rn) values are displayed on a scatter plot, grouped into four distinct genotype clusters: 
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homozygote for allele 1, homozygote for allele 2, heterozygote and no template controls 
(NTCs) to determine the background signal (Applied Biosystems, 2006). 
 
2.5 Statistical analysis 
Genotypic counts of controls were tested for Hardy-Weinberg equilibrium (HWE) using 
a χ2 Test. Haplotype estimates were determined and the frequencies of the most 
common haplotypes were derived using the program FASTPHASE (Scheet and 
Stephens, 2006). LD statistics were computed using Haploview 4.0 (Barrett et al, 2005). 
Multiple logistic regression was applied to compare individuals of the control group 
against three different risk groups defined in Table 3.  
Separate models were estimated where each of the five polymorphisms described in 
Table 4 was included as three-level-factor (homozygous wild-type, heterozygous, 
homozygous polymorph) and each haplotype was included as explanatory variable. Age 
and sex were used as confounders. Odds ratios (ORs) and 95% confidence intervals (CIs) 
were estimated for each polymorphism and haplotype; reference categories were wild-
type and the most frequent haplotype, respectively. 
Analysis of data was performed using the software R Ver 2.6.2. All p-values are 2-sided; 
p-values <0.05 were considered to be statistically significant. 
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3. Results 
3.1 Study population 
Demographic variables and lifestyle factors were analyzed in a study population of 3471 
subjects. In total there were 1555 (44.8%) female and 1916 (55.2%) male probands, with 
significantly less male probands in the control group (Table 6; Figure 2). 
 
Among the 3471 study subjects, 70 were excluded from TERT genotype analysis. 68 
participants were without histological data and two participants without an indication of 
age. The remaining study population consisted of a total of 3401 eligible participants, 
consisting of 182 carcinoma patients, 332 high-risk polyp, 1065 low-risk polyp patients 
and 1822 colonoscopy negative controls. 
 
Table 6. Sex distribution of the study population 
 
Sex 
 
 
 
Othersa 
 
 
 
Controls 
 
 
 
Carcinomas 
 
 
 
High-risk 
polyps  
 
 
Low-risk 
polyps 
 
 
Total 
 
 
 
Female 
 
24 
 
972 
 
74 
 
115 
 
370 
 
1555 
Male 44 851 108 218 695 1916 
 
Male rate 
 
 
 
0.47 
 
0.59 
 
0.65 
 
0.65 
 
 
CIb 
 
 0.44-0.49 0.52-0.66 0.60-0.71 0.62-0.68  
                                                
a Participants without histology 
b 95% confidence interval 
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Figure 2. Proportion of male subjects in the study population with appropriate confidence intervals 
 
The mean ages of the study participants are summarized in Table 7. Carcinoma patients 
(67.04±1.63 years) showed a significant higher mean age compared to the polyp and the 
control group. In contrast the mean age of the control group (61.35±0.52 years) was 
significant lower than the mean age in the three risk groups (Figure 3). 
 
Table 7. Age distribution of the study population 
 
Age 
(Years) 
 
 
Othersa 
 
 
 
Controls 
 
 
 
Carcinomas 
 
 
 
High-risk 
polyps  
 
 
Low-risk 
polyps  
 
 
Total 
 
 
 
≤50 
 
5 
 
356 
 
15 
 
45 
 
143 
 
564 
≤60 14 442 38 70 240 804 
≤70 25 585 53 126 394 1183 
≤80 24 418 58 87 273 860 
>80  21 18 4 15 58 
 
Mean 
 
65.32 
 
61.35 
 
67.04 
 
63.24 
 
63.19 
 
62.47 
SDb 9.80 11.23 11.14 10.06 10.30 10.91 
CIc 
 
 60.83-61.86 65.41-68.67 62.15-64.32 62.58-63.81  
                                                
a Participants without histology 
b Standard deviation 
c 95% confidence interval 
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Figure 3. Histogram with age patterns and associated confidence intervals in the study population  
 
The study population consisted of 1815 non-smokers, 555 current and 1021 former 
smokers (Table 8), with a slightly lower proportion of smokers seen in the control group 
(Figure 4). 80 participants were without an indication of their smoking status. 
 
Table 8. Smoking status of study participants 
 
Smoking 
Status 
 
 
Othersa 
 
Controls 
 
Carcinomas 
 
High-risk 
polyps 
 
Low-risk 
polyps 
 
Total 
 
Current 
 
7 
 
245 
 
29 
 
62 
 
212 
 
555 
Former 23 492 71 104 331 1021 
Never 34 1042 80 158 501 1815 
 
Smoker 
rateb 
  
0.41 
 
0.56 
 
0.51 
 
0.52 
 
CIc 
 
 0.39-0.44 0.48-0.63 0.46-0.57 0.49-0.55  
                                                
a Participants without histology 
b Former and current smokers 
c 95% confidence interval 
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Figure 4. Rate of smokers among the study population 
 
The mean body mass index (BMI) assessed for this study population was 28.68 kg/m2. 
Data analysis showed no statistically significant differences between the BMIs in the 
high-risk groups and the controls.  
The intake of meat and the education of the study participants were not significantly 
different between the controls, the carcinomas and the two polyp groups. 
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3.2 TERT genotypes 
TERT genotypes (rs2735940, rs2736098, rs4975605, rs2736100, rs2075786) were 
determined using TaqMan® MGB probes (Applied Biosystems, California US). One probe 
was labeled with a VIC dye and the other probe was labeled with a FAM™ reporter dye 
at the 5´base, respectively.  
An allelic discrimination was performed on a post PCR product. Corresponding Rn 
values were displayed as points on a scatter plot, grouped into four different clusters 
corresponding to three different specific genotypes based on the graph location: 
homozygote wild-type, homozygote polymorphic, heterozygote and the NTCs. Figure 6 
shows a representative example for a rs2735940 allelic discrimination plot. The PCR 
reaction included a VIC labeled probe for the A/T allele (x-axis) versus a FAM™ labeled 
probe for the G/C allele (y-axis) of rs2735940.  
 
 
Figure 5. Example for a TERT rs2735940 allelic discrimination assay plot 
 
The genotype distributions of the five analyzed SNPs in this study population were found 
to be in HWE. All ORs were calculated relative to the subjects with the polymorphic 
wild-type, i.e. homozygous for the major allele. 
Homozygous  
wild-type 
samples Heterozygous 
samples 
Homozygous 
polymorphic 
samples 
NTCs 
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Multiple logistic regression was applied to compare the individuals of the control group 
against three different risk groups: carcinomas, high-risk polyp group, low-risk polyp 
group. The frequency distributions of the five genotyped SNPs are given in Table 9.  
The data analysis showed no statistically significant association between the investigated 
TERT SNPs and CRC risk. However, for the polymorphism rs2075786 an association 
with an altered risk for high-risk polyps was found. The genotype distribution of the 
polymorphism in the study population was as follows: CC, 40% (1362); TC, 46.1% (1569) 
and TT, 13.8% (470), respectively. Carriers of the TT genotype were associated with an 
increased risk (OR: 1.44; 95% CI: 1.01-2.06) for high-risk polyps.  
 
Table 9. Distribution of the TERT genotypes in association with colonic polyp and CRC risk 
 
Genotype 
 
Controls 
 
Carcinomas 
 
High-risk polyps 
 
Low-risk polyps 
 
 n n OR 95% CI n OR 95% CI n OR 95% CI 
 
rs2735940 
    
CC 475 56 1 0 100 1 0 281 1 0 
CT 920 86 0.79 0.55-1.13 147 0.77 0.58-1.02 530 0.99 0.82-1.20 
TT 
 
427 40 0.80 0.52-1.24 85 0.96 0.70-1.33 254 1 0.81-1.25 
 
rs2736098 
    
GG 1012 107 1 0 189 1 0 586 1 0 
GA 681 63 0.84 0.61-1.18 123 0.97 0.75-1.24 406 1.03 0.88-1.21 
AA 
 
129 12 0.80 0.42-1.51 20 0.83 0.50-1.36 73 0.91 0.67-1.25 
 
rs4975605 
    
GG 598 65 1 0 109 1 0 322 1 0 
GT 867 92 0.96 0.69-1.36 162 1.03 0.79-1.34 543 1.16 0.97-1.38 
TT 
 
357 25 0.62 0.38-1.01 61 0.94 0.66-1.32 200 1.02 0.82-1.28 
 
rs2736100 
    
TT 480 45 1 0 89 1 0 292 1 0 
TG 925 99 1.14 0.79-1.67 154 0.91 0.68-1.21 535 0.96 0.80-1.16 
GG 
 
417 38 0.97 0.61-1.54 89 1.18 0.85-1.63 238 0.94 0.76-1.17 
 
rs2075786 
    
CC 747 69 1 0 121 1 0 425 1 0 
TC 833 87 1.10 0.79-1.55 157 1.18 0.91-1.53 492 1.05 0.89-1.24 
TT 
 
242 26 1.18 0.73-1.91 54 1.44 1.01-2.06 148 1.10 0.87-1.40 
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The MAFs in this study population were in concordance with those reported in the 
SNP500Cancer database (Table 10), with the exception of the intronic polymorphism 
rs2075786. 
 
Table 10. MAF distribution for the TERT SNPs in the control group and in the SNP500Cancer database 
 
SNP 
 
 
MAF 
(Control group) 
 
MAF 
(SNP500Cancer database)a 
 
 
rs2735940 -1381C>T 
 
 
0.487 
 
 
0.452 
 
 
rs2736098 Ex2-659G>A 
 
 
0.258 
 
 
0.258 
 
 
rs4975605 IVS6-3133G>T 
 
 
0.434 
 
0.467 
 
 
rs2736100 IVS2-3777G>T 
 
 
0.483 
 
0.483b 
 
rs2075786 IVS10+269T>C 
 
 
0.361 
 
0.306 
 
                                                
a Caucasian subpopulation 
b Failed HWE in the SNP500Cancer population 
 
To investigate multilocus associations, haplotype analyses were performed for the four 
tSNPs (rs2736098, rs4975605, rs2736100, rs2075786) within TERT. The most frequent 
haplotype (1113) was applied as a reference category. Corresponding adjustments for 
variables with potential confounding effects, like age and sex, were conducted. 
The haplotypes were similarly distributed among the colonoscopy negative controls and 
the three different risk groups, obviously the evaluated combination had no influence on 
the development of colorectal polyps or CRC (Table 11).  
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Table 11. Distribution of the TERT haplotypes  
 
Haplotype 
 
 
Controls 
 
Carcinomas 
 
High-risk polyps 
 
Low-risk polyps 
 n n OR 95% CI n OR 95% CI n OR 95% CI 
 
1a113b 
1111 
1131 
1133 
1311 
1313 
1331 
3131 
3133 
3331 
3333 
Rest 
 
971 
198 
559 
122 
536 
79 
223 
292 
101 
201 
244 
118 
 
92 
20 
65 
6 
62 
10 
20 
30 
7 
21 
24 
7 
 
1 
1.03 
1.30 
0.50 
1.23 
1.38 
0.94 
1.02 
0.71 
1.17 
0.95 
0.64 
 
 
0 
0.61-1.73 
0.92-1.83 
0.21-1.17 
0.87-1.73 
0.68-2.79 
0.56-1.58 
0.66-1.59 
0.31-1.59 
0.70-1.94 
0.59-1.54 
0.29-1.42 
 
172 
41 
103 
24 
96 
11 
47 
38 
14 
47 
52 
19 
 
1 
1.17 
1.05 
1.10 
1.02 
0.79 
1.24 
0.71 
0.84 
1.40 
1.20 
0.89 
 
0 
0.80-1.70 
0.80-1.37 
0.68-1.76 
0.77-1.34 
0.41-1.52 
0.86-1.77 
0.48-1.03 
0.47-1.51 
0.97-2.01 
0.85-1.70 
0.53-1.49 
 
580 
107 
318 
67 
325 
54 
115 
162 
61 
131 
145 
65 
 
1 
0.92 
0.96 
0.92 
1.03 
1.12 
0.90 
0.89 
1.08 
1.13 
0.97 
0.89 
 
0 
0.71-1.19 
0.81-1.15 
0.66-1.27 
0.86-1.23 
0.77-1.62 
0.70-1.16 
0.71-1.11 
0.77-1.52 
0.88-1.45 
0.77-1-23 
0.64-1.24 
 
                                                
a Wild-type 
b Polymorph 
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4. Discussion  
The present diploma thesis examined five allelic variants within the telomere-related 
TERT gene and their implications on colonic polyp and CRC risk in an Austrian 
population. Overall, the results demonstrated no significant influence of the five 
genotyped polymorphisms on CRC susceptibility. However, polymorphic homozygous 
carriers of the intronic SNP (rs2075786) were associated with an increased risk for high-
risk polyps. 
 
Telomeres are crucial for genomic stability and integrity and their maintenance has 
emerged as a key biochemical and critical process in the regulation of cancer (Callén and 
Surrallés, 2004). The activation of telomerase has thereby been proposed as an essential 
step in the immortalization and progression of cancer cells (Meyerson M, 2000). Data 
suggests that in about 90% of human cancers activated telomerase is responsible for 
telomere maintenance (Shay and Bacchetti, 1997), whereas TERT is the catalytic subunit 
and the reverse transcriptase component of the holoenzyme, located at the 5p15.33 locus 
(Cong et al, 2002; Ducrest et al, 2002).  
So far, several epidemiologic studies have investigated the impact of high telomerase 
activity on CRC (Chadeneau et al, 1995; Engelhardt et al, 1997; Brümmendorf TH, 2005) 
and proposed an increased level of telomerase activity as an independent prognostic 
indicator of poor outcome in patients with CRC (Tatsumoto et al, 2000). In addition, a 
prognostic potential of telomere length (Gertler et al, 2004) and TERT expression 
(Gertler et al, 2002; Gertler et al, 2004) was reported. On the contrary, less is known 
about how genetic variants within TERT contribute to an interindividual CRC 
susceptibility. Telomere stability genes (TERT, POT1, TNKS, TERF1, TINF2, TERF2 and 
TERF2IP) are highly conserved in sequence between species, showing a limited degree 
of nucleotide diversity. Hence, genetic variations in these genes, vital for chromosomal 
integrity may have a profound effect (Savage et al, 2005). In addition, given the 
relevance of this genomic region to cancer biology, TERT seems to be a plausible 
candidate for cancer association studies (Rafnar et al, 2009).  
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To capture most of the common genetic variation within TERT and to allow an 
economical interrogation of genotypes, the study focused on representative tSNPs, 
including non-coding (rs4975605, rs2736100, rs2075786) and coding SNPs 
(rs2736098). Moreover, an additional SNP in the promoter region (rs2735940) was 
selected due to the fact that functional SNPs may reside within regulatory elements. 
Another criterion for selecting SNPs was a relatively high MAF in Caucasians. The MAFs 
in this study population were in concordance with those reported in the SNP500Cancer 
database, except for the polymorphism rs2075786, which showed a slight difference. In 
addition, the intronic polymorphism rs2736100 failed the HWE in the SNP500Cancer 
database. With the exception of the polymorphism in intron 6 (rs4975605), all of the 
investigated allelic variants have previously shown to be associated with cancer risk (e.g. 
lung and breast cancer), having either a protective or predisposing effect. To my 
knowledge this is the first study investigating SNPs within the telomerase gene as 
possible susceptibility factors for colorectal polyps and CRC risk.  
 
In the present study population polymorphic carriers of the promoter polymorphism 
rs2735940 (-1381C<T), were found to be associated with a decreased CRC risk compared 
to the wild-type, even though this effect was statistically not significant. The frequency 
distribution of the -1381T/T genotype in the control group (23.44%) was similar to that 
reported for Caucasian control subjects (21%-24.3%) in previous studies (Nordfjäll et al, 
2007; Savage et al, 2007). Moreover, in a Japanese study conducted by Matsubara et al, 
2006 the T/T genotype distribution among healthy individuals was only 15.2%. The T-
sequence was associated with a higher transcriptional activity, lack of age-dependent 
telomere shortening and telomerase activity. However, due to the small sample size (46 
subjects), the obtained results may be a consequence of chance. Nevertheless, findings 
from Savage et al, 2007 supports the functional role of this promoter SNP, suggesting 
that variants in TERT could have an effect in individuals already at increased genetic risk 
of breast cancer, although the number of individuals with a family history of breast 
cancer was small. Interestingly, there are some ambiguous references regarding the 
nucleotide numbering of this polymorphism, corresponding to the reference number 
rs2735940. Matsubara et al, 2006 used the nucleotide numbering according to 
Horiwaka et al, 1999, though the SNP is located at nucleotide -1327, upstream of the 
transcription-starting site of TERT. The same nucleotide numbers were used by 
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Nordfjäll et al, 2007 for analyzing the promoter length in myocardial infarction patients 
and controls. In contrast, Savage et al, 2007 indicated the polymorphism with the 
nucleotide numbering -1381C>T, congruent with the information in the SNP500Cancer 
database. 
 
Referring to the rs2736098 polymorphism in exon 2 our results did not support any 
statistically significant association with CRC or colonic polyp risk. Nevertheless, carriers 
of the A/A genotype showed a slightly decreased risk for CRC compared to the wild-type, 
even though not significant. The genotype frequency of the variant allele (7.08%) in the 
control group was similar to that reported in a previous breast cancer study in 
Caucasians (6%) (Savage et al, 2007). Savage et al, 2007 revealed a protective effect of 
this coding SNP for homozygous carriers of the less common A-allele (OR: 0.57; 95% CI: 
0.39-0.84), having a positive family history. Functional significance of this SNP was 
additionally supported by a GWA study conducted by Rafnar et al, 2009. The rs2736098 
polymorphism was associated with a number of serious cancer types, including basal cell 
carcinoma, lung cancer, bladder cancer and prostate cancer.  
 
Beside the promoter polymorphism (rs2735940) and the coding SNP (rs2736098), three 
intronic SNPs (rs4975605, rs2736100, rs2075786) were investigated in this molecular 
epidemiologic study. Malkinson and You, 1994 hypothesized that introns of genes, 
whose products influence tumor development may affect cancer incidence. Additionally, 
it was assumed that intronic SNPs could influence splicing (Schork et al, 2000). But so 
far only a few studies concerning intronic polymorphism within TERT and cancer risk 
have been published (Savage et al, 2007; McKay et al, 2008; Hosgood 3rd et al, 2009). 
Recently, the less common allele of rs2736100 was detected as disease marker (OR: 1.29; 
95% CI: 1.17-1.43) for lung cancer in a GWA study (McKay et al, 2008). Homozygous 
carriers of the rs2736100 polymorphism showed a decreased risk for CRC, even though 
not significant. 
None of the investigated polymorphisms in this study was significantly associated with 
CRC susceptibility. However, the +269T/T genotype of the rs2075786 polymorphism 
was significantly associated with a 1.44-fold risk of high-risk polyps when compared to 
the wild-type. The MAF for the rs2075786 polymorphism in our control group (0.361) 
was somewhat lower than the MAF indicated in the SNP500Cancer database for the 
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Caucasian subpopulation (0.404), but somewhat higher than in the HapMap Caucasian 
subpopulation (0.306). The slight differences may be a consequence of the relatively 
small group size in SNP500 and HapMap, compared to the present study population. 
However, the genotype frequency of +269T/T in our control group (13.28%) was in 
accordance with the frequencies found in other Caucasian populations (HapMap= 14%; 
SNP500Cancer database= 12.9%). Furthermore, it was similar to that reported for 
healthy Caucasians (12%) in a previous breast cancer study (Savage et al, 2007). In 
contrast, the variant genotype frequency was much lower in a Chinese population 
(6.4%). The homozygous carriers of the polymorphic allele were associated with a 
decreased lung cancer risk (Hosgood 3rd et al, 2009). Contrary to these findings, Savage 
et al, 2007 reported no significant interaction between the polymorphism and breast 
cancer risk. 
In general, associations found between the polymorphism and overall cancer risk could 
be due to chance or be attributed to etiologic and ethnical differences. SNPs that display 
different associations between populations may be the marker, rather than the 
functional polymorphisms, because they are in different LD blocks or occur on different 
haplotypes in different populations (King et al, 2005). In addition, the lung cancer 
association study conducted by Hosgood 3rd et al, 2009 included a relatively small 
number of study subjects (110 controls, 120 cases). Thus, further investigations with 
larger sample sizes are needed to obtain reliable results.  
These data reflect the critical issue of a large sample size, important for the sufficient 
identification of common genetic polymorphisms involved in cancer susceptibility. 
According to Rothman et al, 2001, the sample size needed to study a particular genotype 
with an OR of 1.5 and a prevalence of about 10% in the general population would be 
about 900 cases and controls. Lango and Weedon, 2008 even propose thousands of 
subjects for a reliable detection of polygenic variants with small effects. Beside an 
inadequate study design such as a small sample size, ethnically mixed study populations, 
selection of controls, control for confounding factors and statistical methods can be 
potential sources of bias. One of the major strengths of this case-control study was the 
large sample size, although as expected for a screening project, predominantly consisting 
of patients with colonic polyps and polyp free participants. In spite of screening a certain 
age group, the mean age of the control group was significantly lower than the mean age 
in the three risk groups. In addition, carcinoma patients showed a significantly higher
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mean age compared to the polyp and control group. The difficulty of selecting an 
appropriate control group was resolved by a hospital-based control group, involving 
polyp and cancer free participants, who had undergone colonoscopy. Using a control 
group which did not undergo colonoscopy could include some undiagnosed participants 
with colonic polyps or CRC, because in this age group (40-80 years) those conditions are 
relatively common. Furthermore, to adjust different malignant potential of the colonic 
polyps diagnosed in this screening project, polyps were classified into a high and a low-
risk group, according to their villous architecture. Patients with villous histology are at a 
greater risk to develop CRC and were therefore assigned to the high-risk group. The St. 
Marks Hospital Study supported the association of villous histology with an increased 
risk of malignancy; 4.8% of tubular adenomas, 22.5% of tubulovillous and 40.7% of 
villous adenomas were malignant (Markowitz and Winawer, 1997). However, 
implications of this histological classification were a lower sample size of high-risk 
polyps (n= 333) compared to the low-risk polyp group (n= 1065). Another limitation in 
the present study design is the relatively small number of carcinoma cases within the 
study population, which could be a potential explanation for the nonexistent significant 
associations between TERT SNPs and CRC risk. According to Wacholder et al, 2004 an 
increased number of cases and control subjects would additionally reduce a false-
positive report probability substantially. In some extent, this was resolved by the 
incorporation of further cases from three hospitals in Vienna. Furthermore, the number 
of investigated SNPs in this study population was too small to allow a definitive 
conclusion. As the diploma thesis is part of the project “Molecular Epidemiology of 
Colorectal Cancer”, additional polymorphisms will be sought in an effort to draw 
definitive conclusions about genetic variations within telomere stability genes as 
prognostic markers for CRC risk.  
With regard to the rs2075786 polymorphism, the significant positive association 
between homozygous carrier of the T-allele and an increased high risk polyp risk should 
be cautiously interpreted until these results are replicated, since observed associations 
with particular SNPs may be due to another SNP in LD (Hosgood 3rd et al, 2009). In 
addition, according to Lango and Weedon, 2008 statistical significance levels in case-
control association studies need to be interpreted with much more caution. 
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In conclusion, this diploma thesis has shown no statistically significant associations of 
the five genotyped polymorphisms in TERT and CRC risk. Thus, the role of genetic 
variation within TERT in the susceptibility to CRC remains unclear. However, a 
significant association for the homozygous carrier of the intronic SNP rs2075786 and an 
increased risk of developing high-risk polyps was demonstrated. Due to the fact that 
patients with high-risk polyps are at greater risk to develop CRC, this polymorphism 
may be an indirect molecular marker of CRC. But this must be confirmed in further 
studies. 
The risk for a complex and multifactorial non Mendelian disease, like CRC may be 
modulated not only from a SNP within one gene, but also as a joint effect of multiple 
polymorphisms within different genes and pathways. Therefore, further investigations in 
larger studies are needed to combine effects of polymorphisms within telomere biology 
genes and to develop a polygenic model of CRC risk. Positional cloning and the 
application of linkage analysis has been extremely useful in the identification of genes 
responsible for monogenetic traits, but has a limited success for complex human 
diseases without obvious Mendelian inheritance, with often disappointing and 
inconsistent results (Altmüller et al, 2001). The method of choice and a promising field 
in the identification of common variants predisposing to complex diseases are GWA 
studies, accompanied by new high throughput genotyping technologies, such as 
microarrays (Lango and Weedon, 2008). Microarrays allow genotyping of a large 
number of SNPs across the genome simultaneously, raising the possibility that genetics 
will find a major role at the clinic distinguishing between individuals at low to high risk 
of cancer (Schork et al, 2000; Lango and Weedon, 2008). 
 
A further research project using the genome wide SNP Array 6.0 will be started, in order 
to identify additional susceptibility markers for high-risk colonic polyps and CRC.  
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